Brand Name

Omidria

Generic Name
Ketorolac
View Brand Information
FDA approval date: June 13, 2014
Classification: alpha-1 Adrenergic Agonist
Form: Injection

What is Omidria (Ketorolac)?

Omidria ® is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. OMIDRIA is an alpha 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor indicated for: Maintaining pupil size by preventing intraoperative miosis Reducing postoperative pain OMIDRIA is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Assessment of Postoperative Pain Outcomes Following Pediatric Adenotonsillectomy and the Impact on Non-Steroidal Anti-Inflammatory Drugs
Assessment of Postoperative Pain Outcomes Following Pediatric Adenotonsillectomy and the Impact on Non-Steroidal Anti-Inflammatory Drugs
Enrollment Status: Recruiting
Publish Date: September 08, 2026

Summary: This prospective observational study will evaluate postoperative pain after outpatient pediatric adenotonsillectomy in adolescents prescribed either acetaminophen with ibuprofen or acetaminophen with oral ketorolac after discharge, based on the prescribing preference of the otolaryngology surgeon. Participants will complete text-message surveys after discharge to assess pain severity, medication a...

Single Blind RCT to Evaluate the Effect of Ketorolac in Upper Extremity Tendinopathy and Arthropathy
Single Blind RCT to Evaluate the Effect of Ketorolac in Upper Extremity Tendinopathy and Arthropathy
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Drug
Study Phase: Phase 4

Summary: Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes corticosteroid and ketorolac injections which have been well investigated as a modality of pain control...

Efficacy and Safety of Ketorolac in Improving Prognosis of Stanford Type A Aortic Dissection: a Multicenter, Randomised, Double-blind, Controlled Clinical Trial
Efficacy and Safety of Ketorolac in Improving Prognosis of Stanford Type A Aortic Dissection: a Multicenter, Randomised, Double-blind, Controlled Clinical Trial
Enrollment Status: Recruiting
Publish Date: August 31, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 1,346 patients with Stanford Type A aortic dissection, conducted between 2025 and 2028. Participants will receive either ketorolac (60 mg intramuscularly \[IM\] within 6 hours before surgery and 30 mg im twice daily（at 6:00 AM and 6:00 PM, respectively for two days postoperatively...

View All Clinical Trials

Related Latest Advances

Subcutaneous Administration of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) for Pain Management: A Systematic Review and Meta-Analysis.
Subcutaneous Administration of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) for Pain Management: A Systematic Review and Meta-Analysis.
Journal: Journal of pain & palliative care pharmacotherapy
Published: September 01, 2026
When the Law Changes Therapy: Interrupted Time-Series Analysis of the Regulatory Impact on Intravenous Analgesic Consumption in 2 Italian Orthopaedic Hospitals (2021-2024).
When the Law Changes Therapy: Interrupted Time-Series Analysis of the Regulatory Impact on Intravenous Analgesic Consumption in 2 Italian Orthopaedic Hospitals (2021-2024).
Journal: Hospital pharmacy
Published: August 12, 2026
The Impact of Age and Exercise Training on Endothelial-Mediated Mechanisms of Vasodilation during Passive Leg Movement in Males.
The Impact of Age and Exercise Training on Endothelial-Mediated Mechanisms of Vasodilation during Passive Leg Movement in Males.
Journal: American journal of physiology. Regulatory, integrative and comparative physiology
Published: July 30, 2026
View All Latest Advances

Brand Information

Omidria (phenylephrine and ketorolac)
1INDICATIONS AND USAGE
Omidria
2DOSAGE AND ADMINISTRATION
Omidria must be diluted prior to intraocular use. For administration to patients undergoing cataract surgery or intraocular lens replacement, 4 mL of Omidria is diluted in 500 mL of ocular irrigating solution. Irrigation solution is to be used as needed for the surgical procedure for a single patient.
The storage period for the diluted product is not more than 4 hours at room temperature or 24 hours under refrigerated conditions.
Do not use if the solution is cloudy or if it contains particulate matter.
3DOSAGE FORMS AND STRENGTHS
Omidria is an intraocular solution containing 10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac for use in a single patient.
4CONTRAINDICATIONS
Omidria is contraindicated in patients with a known hypersensitivity to any of its ingredients.
5OVERDOSAGE
Systemic overdosage of phenylephrine may cause a rise in blood pressure. It may also cause headache, anxiety, nausea, vomiting, and ventricular arrhythmias. Supportive care is recommended.
6DESCRIPTION
Omidria is a sterile aqueous solution, containing the α
The descriptions and structural formulae are:
Phenylephrine Hydrochloride Drug Substance:
Figure 1: Chemical Structure for Phenylephrine HCl
Figure 1
Ketorolac Tromethamine Drug Substance:
Figure 2: Chemical Structure for Ketorolac Tromethamine
Figure 2
Omidria is a clear, colorless to slightly yellow, sterile solution concentrate with a pH of approximately 6.3.
Each vial of Omidria contains:
Actives: phenylephrine hydrochloride 12.4 mg/mL equivalent to 10.16 mg/mL of phenylephrine and ketorolac tromethamine 4.24 mg/mL equivalent to 2.88 mg/mL of ketorolac.
Inactives: citric acid monohydrate; sodium citrate dihydrate; water for injection; may include sodium hydroxide and/or hydrochloric acid for pH adjustment.
7HOW SUPPLIED/STORAGE AND HANDLING
Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is supplied in a clear, 5-mL glass, single-patient-use vial containing 4 mL of sterile solution, for addition to ocular irrigating solution.
Omidria is supplied in a multi-pack containing:
4 vials : NDC 62225-600-04 or
10 vials: NDC 62225-600-10
8PATIENT COUNSELING INFORMATION
Inform patients that they may experience sensitivity to light.
Omeros Corporation
© Omeros 2013-2017
OMIDRIA
9PRINCIPAL DISPLAY PANEL
NDC 62225-600-04
OMIDRIA®
(phenylephrine and ketorolac intraocular solution)
1% / 0.3%
For Intraocular use.
Must Be Diluted.
Single-Patient vial
Sterile 4 mL
Quantity: 4
Rx Only
PRINCIPAL DISPLAY PANEL